RxSight, Inc. (NASDAQ:RXST) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 192,510 shares of the company’s stock after purchasing an additional 7,494 shares during the period. JPMorgan Chase & Co. owned 0.48% of RxSight worth $9,516,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in RXST. Nisa Investment Advisors LLC raised its stake in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quarry LP increased its holdings in shares of RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after buying an additional 288 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of RxSight during the 3rd quarter valued at approximately $34,000. Quest Partners LLC acquired a new position in RxSight in the second quarter valued at approximately $41,000. Finally, KBC Group NV grew its position in RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock worth $61,000 after acquiring an additional 479 shares during the period. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

RxSight Stock Down 8.1 %

Shares of RxSight stock opened at $30.72 on Tuesday. The firm has a market cap of $1.24 billion, a PE ratio of -37.01 and a beta of 1.20. RxSight, Inc. has a fifty-two week low of $26.29 and a fifty-two week high of $66.54. The business’s fifty day moving average is $40.61 and its two-hundred day moving average is $47.38.

Analyst Upgrades and Downgrades

RXST has been the topic of a number of research analyst reports. UBS Group assumed coverage on RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price on the stock. Wells Fargo & Company reduced their price objective on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday. Stifel Nicolaus lowered their target price on shares of RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Monday. Finally, Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.13.

Insider Activity

In related news, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the sale, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $50.09, for a total value of $155,529.45. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,116,102.14. This trade represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,002 shares of company stock valued at $1,959,796 in the last three months. Corporate insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.